Media headlines about Mediwound (NASDAQ:MDWD) have been trending somewhat positive recently, Accern reports. The research group identifies negative and positive news coverage by reviewing more than 20 million blog and news sources. Accern ranks coverage of public companies on a scale of negative one to positive one, with scores closest to one being the most favorable. Mediwound earned a coverage optimism score of 0.14 on Accern’s scale. Accern also assigned headlines about the biopharmaceutical company an impact score of 48.0579643594597 out of 100, meaning that recent news coverage is somewhat unlikely to have an effect on the stock’s share price in the immediate future.
Here are some of the news headlines that may have effected Accern Sentiment Analysis’s analysis:
- Oppenheimer Boosts Mediwound (MDWD) Price Target to $12.00 (americanbankingnews.com)
- Zacks Investment Research Upgrades Mediwound (MDWD) to “Hold” (americanbankingnews.com)
- Mediwound Ltd to Post Q1 2018 Earnings of ($0.25) Per Share, Jefferies Group Forecasts (MDWD) (americanbankingnews.com)
- Research Analysts Set Expectations for Mediwound Ltd’s Q1 2018 Earnings (MDWD) (americanbankingnews.com)
- Oppenheimer Analysts Decrease Earnings Estimates for Mediwound Ltd (MDWD) (americanbankingnews.com)
Mediwound stock opened at $5.25 on Friday. Mediwound has a 52 week low of $3.56 and a 52 week high of $8.25. The company has a market cap of $142.00, a P/E ratio of -5.36 and a beta of 0.15.
A number of equities analysts recently commented on MDWD shares. Oppenheimer set a $10.00 price objective on shares of Mediwound and gave the stock a “buy” rating in a research note on Friday, December 8th. Zacks Investment Research raised shares of Mediwound from a “sell” rating to a “hold” rating in a research note on Thursday. Wells Fargo decreased their price objective on shares of Mediwound from $9.00 to $8.00 and set an “outperform” rating for the company in a research note on Tuesday, March 20th. Finally, ValuEngine raised shares of Mediwound from a “strong sell” rating to a “sell” rating in a research note on Saturday, November 25th. One analyst has rated the stock with a sell rating, one has assigned a hold rating and six have given a buy rating to the company’s stock. The company has a consensus rating of “Buy” and a consensus target price of $9.25.
ILLEGAL ACTIVITY NOTICE: “Somewhat Positive Press Coverage Somewhat Unlikely to Affect Mediwound (MDWD) Share Price” was published by Ticker Report and is the sole property of of Ticker Report. If you are accessing this piece on another publication, it was stolen and republished in violation of international copyright and trademark legislation. The correct version of this piece can be accessed at https://www.tickerreport.com/banking-finance/3299587/somewhat-positive-press-coverage-somewhat-unlikely-to-affect-mediwound-mdwd-share-price.html.
Mediwound Company Profile
MediWound Ltd. is a biopharmaceutical company. The Company focuses on developing, manufacturing and commercializing therapeutics products in the fields of severe burns, chronic and other hard-to-heal wounds, connective tissue disorders and other indications. The Company’s product, NexoBrid, is indicated for the removal of dead or damaged tissue, known as eschar, in adults with deep partial- and full-thickness thermal burns, also referred to as severe burns.
Receive News & Ratings for Mediwound Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Mediwound and related companies with MarketBeat.com's FREE daily email newsletter.